1326 GMT - Novo Nordisk's CEO departure comes as a surprise despite the steep share price decline over the past year, traders in Frankfurt say. Although the share's decline has been steep, the valuation nearly quintupled in the time leading up to it. "The CEO can't do anything about competition entering a market with (product) profitability like that," a trader says. The Danish pharma company--known for its weight-loss treatments--said it is currently seeking a successor for the CEO post. Shares trade 1.9% lower at 425.75 Danish kroner, after falling more than 4% following the news. (michael.denzin@wsj.com)
(END) Dow Jones Newswires
May 16, 2025 09:27 ET (13:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。